Aspen Pharmacare Holdings Limited - Announcement
Aspen Pharmacare Holdings Limited
(Incorporated in the Republic of South Africa)
(Registration number 1985/002935/06)
Share code: APN ISIN: ZAE000023586
Aspen Pharmacare is pleased to announce the following Aspen generic anti-
retrovirals have been registered with the MCC.
Aspen Nevirapine Tablets 200mg
Aspen Lamivudine Tablets 150mg
Aspen Lamivudine Solution 100mg/ml
Aspen Zidovudine Tablets 300mg
Aspen Zidovudine Syrup 50mg/5ml
Aspen Lamzid (Zidovudine 300mg and Lamivudine 150mg combination tablet)
They will be added to Aspen`s previously registered anti-retrovirals:
Aspen Stavudine Capsules 15mg
Aspen Stavudine Capsules 20mg
Aspen Stavudine Capsules 30mg
Aspen Stavudine Capsules 40mg
Aspen Didanosine (Buffered) Tablets 25mg
Aspen Didanosine (Buffered) Tablets 50mg
Aspen Didanosine (Buffered) Tablets 100mg
Aspen Didanosine (Buffered) Tablets 150mg
Aspen is now in a position to provide cocktail therapies.
The newly registered products will be available in the private market by the end
of August and will qualify for the State tender closing in August 2004.
Stephen Saad, Aspen Pharmacare Holdings Limited
Group Chief Executive
Tel: (031) 580 8603
Fax: (031) 580 8640
Cell: 083 303 4833
Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information.
